Ling Wang, Zhaoduan Liang, Yunzhuo Guo, Jean de Dieu Habimana, Yuefei Ren, Obed Boadi Amissah, Omar Mukama, Siqi Peng, Xuanyan Ding, Linshuang Lv, Junyi Li, Min Chen, Zhaoming Liu, Rongqi Huang, Yinchao Zhang, Yi Li, Zhiyuan Li, Yirong Sun
Antigen-specific T cell receptor-engineered T cell (TCR-T) based immunotherapy has proven to be an effective method to combat cancer. In recent years, cross-talk between the innate and adaptive immune systems may be requisite to optimize sustained antigen-specific immunity, and the stimulator of interferon genes (STING) is a promising therapeutic target for cancer immunotherapy. The level of expression or presentation of antigen in tumor cells affects the recognition and killing of tumor cells by TCR-T. This study aimed at investigating the potential of innate immune stimulation of T cells and engineered T cells to enhance immunotherapy for low-expression antigen cancer cells...
April 13, 2024: Cell Death & Disease